Biotech | January 15, 2025
Investment will fund expansion to meet rising demand for CRDMO services
Successfully transformed the organization from a two-country operation focused on development and manufacturing to a fully integrated company with a strong commercial engine bringing us closer to patients in over 120 countries
2.92 acre facility will combine tradition and innovation, offering new opportunities for holistic healing, specialized clinics, and skill development to be constructed at a cost of around Rs. 185 crore
India's bio economy has experienced remarkable growth, skyrocketing from $10 billion in 2014 to over $130 billion in 2024, with projections to reach $300 billion by 2030
The facility is equipped with state-of-the-art technology to produce high-quality lyophilized (freeze-dried) products
Expects to unlock further opportunities in the Moldovan market, contributing anticipated sales of $300,000 in 2025 and approximately $700,000–$800,000 in 2026
Smeeta Bhatkal, Santosh Desai and Akshay Kumar join as Independent Directors; Shaina NC as Non-Executive Director
The session focused on “Biomanufacturing of Enzymes,” a critical domain under the BioE3 Policy.
Both units of Shilpa Medicare (Unit IV and Unit VII), have now received GMP approval from Eurasia
Subscribe To Our Newsletter & Stay Updated
